Opin vísindi

Characteristics of white blood cell count in acute lymphoblastic leukemia : A COST LEGEND phenotype-genotype study

Skoða venjulega færslu

dc.contributor Landspitali - The National University Hospital of Iceland
dc.contributor.author Helenius, Marianne
dc.contributor.author Vaitkeviciene, Goda
dc.contributor.author Abrahamsson, Jonas
dc.contributor.author Jónsson, Ólafur Gisli
dc.contributor.author Lund, Bendik
dc.contributor.author Harila-Saari, Arja
dc.contributor.author Vettenranta, Kim
dc.contributor.author Mikkel, Sirje
dc.contributor.author Stanulla, Martin
dc.contributor.author Lopez-Lopez, Elixabet
dc.contributor.author Waanders, Esmé
dc.contributor.author Madsen, Hans O
dc.contributor.author Marquart, Hanne Vibeke
dc.contributor.author Modvig, Signe
dc.contributor.author Gupta, Ramneek
dc.contributor.author Schmiegelow, Kjeld
dc.contributor.author Nielsen, Rikke Linnemann
dc.date.accessioned 2022-05-19T01:02:58Z
dc.date.available 2022-05-19T01:02:58Z
dc.date.issued 2022-03-22
dc.identifier.citation Helenius , M , Vaitkeviciene , G , Abrahamsson , J , Jónsson , Ó G , Lund , B , Harila-Saari , A , Vettenranta , K , Mikkel , S , Stanulla , M , Lopez-Lopez , E , Waanders , E , Madsen , H O , Marquart , H V , Modvig , S , Gupta , R , Schmiegelow , K & Nielsen , R L 2022 , ' Characteristics of white blood cell count in acute lymphoblastic leukemia : A COST LEGEND phenotype-genotype study ' , Pediatric Blood and Cancer , vol. 69 , no. 6 , e29582 . https://doi.org/10.1002/pbc.29582
dc.identifier.issn 1545-5009
dc.identifier.other 48671453
dc.identifier.other 1e5b9d8a-9861-4c42-bf8d-1d226e9d8947
dc.identifier.other 35316565
dc.identifier.other 85127362443
dc.identifier.other unpaywall: 10.1002/pbc.29582
dc.identifier.uri https://hdl.handle.net/20.500.11815/3186
dc.description Funding Information: The authors would like to thank the patients for their participation in the studies. Furthermore, we thank the staff and researchers at Bonkolab at Rigshospitalet for organizational support as well as for collection and registration of the patient data. Marianne Helenius and Ramneek Gupta gratefully acknowledge funding from the Danish Childhood Cancer Foundation (TRAVERSE, 2018‐3755). This study was also funded by the Kirsten and Freddy Johansen Foundation, the Swedish Childhood Cancer Foundation, the Nordic Cancer Union, the Otto Christensen Foundation, University Hospital Rigshospitalet, and the Novo Nordisk Foundation. This work is part of Interregional Childhood Oncology Precision Medicine Exploration (iCOPE), a cross‐Oresund collaboration between University Hospital Copenhagen, Rigshospitalet, Lund University, Region Skåne, and Technical University Denmark (DTU), supported by the European Regional Development Fund. This work is also part of Childhood Oncology Network Targeting Research, Organisation & Life expectancy (CONTROL) and supported by Danish Cancer Society (R‐257‐A14720) and the Danish Childhood Cancer Foundation (2019‐5934). This study was facilitated by the EU‐COST action LEGEND (CA16223, https://www.legend‐cost.eu ) for leukemia data sharing and collaboration. Funding Information: The authors would like to thank the patients for their participation in the studies. Furthermore, we thank the staff and researchers at Bonkolab at Rigshospitalet for organizational support as well as for collection and registration of the patient data. Marianne Helenius and Ramneek Gupta gratefully acknowledge funding from the Danish Childhood Cancer Foundation (TRAVERSE, 2018-3755). This study was also funded by the Kirsten and Freddy Johansen Foundation, the Swedish Childhood Cancer Foundation, the Nordic Cancer Union, the Otto Christensen Foundation, University Hospital Rigshospitalet, and the Novo Nordisk Foundation. This work is part of Interregional Childhood Oncology Precision Medicine Exploration (iCOPE), a cross-Oresund collaboration between University Hospital Copenhagen, Rigshospitalet, Lund University, Region Skåne, and Technical University Denmark (DTU), supported by the European Regional Development Fund. This work is also part of Childhood Oncology Network Targeting Research, Organisation & Life expectancy (CONTROL) and supported by Danish Cancer Society (R-257-A14720) and the Danish Childhood Cancer Foundation (2019-5934). This study was facilitated by the EU-COST action LEGEND (CA16223, https://www.legend-cost.eu) for leukemia data sharing and collaboration. Publisher Copyright: © 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
dc.description.abstract Background: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well-known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood. Methods: We included patients treated with the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-2008 protocol (N = 2347, 72% were genotyped by Illumina Omni2.5exome-8-Bead chip) aged 1–45 years, diagnosed with B-cell precursor (BCP-) or T-cell ALL (T-ALL) to investigate the variation in WBC. Spline functions of WBC were fitted correcting for association with age across ALL subgroups of immunophenotypes and karyotypes. The residuals between spline WBC and actual WBC were used to identify WBC-associated germline genetic variants in a genome-wide association study (GWAS) while adjusting for age and ALL subtype associations. Results: We observed an overall inverse correlation between age and WBC, which was stronger for the selected patient subgroups of immunophenotype and karyotypes (ρ BCP-ALL= −.17, ρ T-ALL= −.19; p < 3 × 10 −4). Spline functions fitted to age, immunophenotype, and karyotype explained WBC variation better than age alone (ρ =.43, p << 2 × 10 −6). However, when the spline-adjusted WBC residuals were used as phenotype, no GWAS significant associations were found. Based on available annotation, the top 50 genetic variants suggested effects on signal transduction, translation initiation, cell development, and proliferation. Conclusion: These results indicate that host genome variants do not strongly influence WBC across ALL subsets, and future studies of why some patients are more prone to hyperleukocytosis should be performed within specific ALL subsets that apply more complex analyses to capture potential germline variant interactions and impact on WBC.
dc.format.extent 1036980
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries Pediatric Blood and Cancer; 69(6)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Bráðahvítblæði
dc.subject Barnalæknisfræði
dc.subject Genome-Wide Association Study
dc.subject Genotype
dc.subject Humans
dc.subject Leukocyte Count
dc.subject Phenotype
dc.subject Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
dc.subject Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
dc.subject Prognosis
dc.subject acute lymphoblastic leukemia (ALL)
dc.subject genome-wide association studies (GWAS)
dc.subject white blood cell count (WBC)
dc.subject genotype
dc.subject spline functions
dc.subject Hematology
dc.subject Oncology
dc.subject Pediatrics, Perinatology and Child Health
dc.title Characteristics of white blood cell count in acute lymphoblastic leukemia : A COST LEGEND phenotype-genotype study
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1002/pbc.29582
dc.relation.url http://www.scopus.com/inward/record.url?scp=85127362443&partnerID=8YFLogxK


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu